HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $58.
June 03, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Mirum Pharmaceuticals and maintained a price target of $58.
The reiteration of a Buy rating and maintenance of a $58 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100